Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

Story continues below

On August8, 2017, Achillion Pharmaceuticals, Inc. (the “Company”) announced its financial results for the fiscal quarter ended June30, 2017 and provided an update on its factor D inhibitor platform. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press Release dated August8, 2017


ACHILLION PHARMACEUTICALS INC Exhibit
EX-99.1 2 d439228dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   ACHILLION REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROOF-OF-CONCEPT WITH A FIRST-IN-CLASS,…
To view the full exhibit click here

About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

An ad to help with our costs